Abstract. PAX2 is a paired box transcription factor possessing a fundamental role in the embryogenesis of hindbrain and urinary tract. PAX genes are proto-oncogenes, PAX2 expression may contribute to the pathogenesis of renal cell carcinoma. Because of the expression of PAX2 in the developing hindbrain and its essential role in cerebellar development, it has been hypothesized that PAX2 may also be involved in medulloblastoma tumorigenesis. We investigated the expression pattern of PAX2 and various genes of the neuronal lineage in medulloblastoma and glioma cell lines. We found high expression of PAX2 mRNA and PAX2 protein in medulloblastoma cells and some glioma cell lines independent of their neuronal lineage gene expression signature. Gene suppression of PAX2 decreased the expression of the PAX2 transcriptional target GDNF in Daoy cells and had a profound cytotoxic effect in vitro on Daoy medulloblastoma and T98G glioma cells. Expression of PAX2 was then assessed in two separate medulloblastoma tissue microarrays with a total of 61 patient samples by immunohistochemistry. PAX2 expression was detected in the majority of medulloblastoma samples and correlated with less differentiated histology. Therefore, PAX2 is a biomarker for a more aggressive medulloblastoma phenotype and may represent a novel therapeutic target.
Introduction
The paired box transcription factor gene family has been well characterized both in human (PAX) and mouse (Pax) and consists of nine genes in the human genome which encode the corresponding transcription factors (PAX/Pax). PAX genes, like other developmental control genes, are proto-oncogenes (1) . They serve to orchestrate the expression of target gene responses that enable proliferation and suppress apoptosis in their target tissues (2) . The expression patterns of PAX genes are therefore tightly regulated both in a spatial and temporal manner during embryonal development. PAX2, in particular, is important for hindbrain and renal development. Interestingly, in hindbrain development, the closely related paralogous PAX genes 2, 5 and 8, can compensate for the loss of one another and a major cerebellar phenotype with partial or complete cerebellar agenesia occurs when two alleles or more are lost (3). In general, PAX genes are downregulated in differentiated tissues. In particular, expression of PAX2, 5 and 8 is suppressed in postnatal hindbrain (4) .
In line with their biological functions, deregulated overexpression of PAX genes can drive the development of tumors both in children and adults. Specifically, fusion genes involving PAX3 or PAX7 cause alveolar rhabdomyosarcoma (5) . An oncogenic fusion gene involving the Ig enhancer and PAX5 has been found in malignant B-cell lymphomas (6) . PAX8 can also be involved in a translocation which results in the PAX8-PPARγ fusion protein in follicular thyroid carcinoma (7) . Elevated PAX2 expression has been found in cystic and hyperproliferative disorders of the kidney, possible predecessors of renal cell carcinoma (4, 8, 9) . A high proportion of primary renal cell carcinomas express PAX2 (10) . An elevated expression of PAX2 mitigates cisplatin-induced cytotoxicity and blocks caspase-2 induced apoptosis in ACHN and CAKI-1 renal carcinoma and human embryonic kidney 293 (HEK293) cells (11, 12) . Accordingly, inhibition of PAX2 with specific siRNAs in the cell lines EJ (bladder carcinoma) and IGROV-1 (ovarian carcinoma) increased the rate of apoptosis thereby lowering the proliferation rate (13) .
Due to the expression pattern of PAX2, 5 and 8, particular interest has been generated in these genes as candidate genes involved in medulloblastoma, the most common malignant embryonal brain tumor that originates from the hindbrain. We therefore investigated the expression pattern of PAX2 and PAX8 in addition to PAX5 in medulloblastoma cells and compared it to their expression in glioma cells, in which expression of PAX5 has been shown to correlate inversely with the expression of p53 (14) . We found high expression of PAX2 in medulloblastoma cells and the majority of medulloblastoma samples from two separate tissue microarrays. Gene suppression of PAX2 had a profound cytotoxic effect in vitro.
Materials and methods
Cell culture and reagents. Daoy medulloblastoma cells were a gift from T. Pietsch (Bonn, Germany). The human malignant glioma cell lines were kindly provided by N. De Tribolet (Lausanne, Switzerland). The murine glioma cell line SMA-560 was a gift of D. Bigner (Durham, NC, USA). The immortalized astrocytic cell line SV-FHAS was kindly provided by A. Muruganandam (Ottawa, Canada). EJ bladder carcinoma cells were a gift from M. Eccles (Otago, New Zealand). Cells were cultivated as described before (15) . Cell lines were stably transfected by lipofection using FuGENE6 (Roche, Mannheim, Germany). The plasmids encoding human PAX2 transcription variants PAX2b or PAX2c (pCMV/PAX2-N1 and pCMV/PAX2-N3, respectively, plus the empty control vector pHN/CMV) were kindly provided by M. Eccles. The plasmid encoding murine Pax2 (pmPax2/334 plus the empty vector pKW10) was kindly provided by M. Busslinger (Vienna, Austria).
Cell growth and hypoxia was assessed by crystal violet staining as previously described (15) . Cell viability was analysed by lactate dehydrogenase (LDH) release assays or flow cytometry (15) .
RNA interference. The following small interfering RNA sequences targeting the human PAX2 coding region were used: d1: 5'-AAACUGUCCACACCACUCUUU-3'; d2: 5'-UCUGA UUUGAUGUGCUCUGUU-3'. A predesigned scrambled siRNA was used as control (Dharmacon). For transient siRNA transfections Metafectene Pro was employed according to the protocol with a final siRNA concentration of 50 nM and 0.33 µl Metafectene Pro in 100 µl transfection medium per well for 96-well plates.
Real-time PCR. RNA was isolated using the RNeasy Mini Kit (Qiagen). Superscript II RT (Gibco) was employed for cDNA synthesis. cDNA amplification was monitored using SYBR Green chemistry (ABgene) on the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). The conditions for all PCR reactions were as follows: 40 cycles of 95˚C for 15 sec and 60˚C for 1 min, using the following specific primers Immunoblot analysis. Immunoblots were performed as described before (15) . Membranes were probed with anti-PAX2 antibodies (cat. no. 71-6000, Invitrogen) or anti-β-actin antibodies (SC-1616, Santa Cruz Biotechnology).
Immunohistochemistry. Immunohistochemistry was performed as described before on paraffin-embedded specimens or cytopellets (17) . The polyclonal rabbit anti-human PAX2 (Invitrogen) antibody was used. We investigated two independent tissue microarrays containing medulloblastoma specimens of 61 patients and 3 normal appearing cerebellar specimens from the tumor banks of the departments of neuropathology of the University of Frankfurt (n=18) and Münster (n=43). All tissues were evaluated by at least two neuropathologists according to the current classification of tumours of the central nervous system (18) using routine HE, reticulin and immunohistochemical stainings including antibodies against Ki-67, GFAP, MAP2, NeuN, synaptophysin and vimentin. The project was approved by the ethics committee of the university hospital of Frankfurt (project no. 4/09).
TMA evaluation. Immunostained sections were evaluated by two examiners (P. Baumgarten and M. Mittelbronn). A semiquantitative score including staining intensity and frequency similar to commonly used scores in routine pathology was applied (19) . The frequency score ranged from 0-4 (score 0, 0-1%; score 1, 1-10%; score 2, 11-25%; score 3, 26-50% and score 4, >50% of all tumor cells showing a positive staining). The intensity score ranged from 0-3 (0, no staining; score 1, weak staining; score 2, moderate staining and score 3, strong staining). The two results for staining intensity and frequency were multiplied, so that a 'Multi-score' reflected both.
Statistical analysis. Where indicated, a two-tailed Student's t-test was used with P<0.05 considered significant and P<0.01 considered highly significant. Evaluation of survival patterns in mice bearing intracerebral gliomas was performed by the KaplanMeier method. Contingency analysis for PAX2 expression scores derived from the TMA studies according to histomorphological subtypes was performed followed by Pearsons χ 2 test.
Results

PAX2 is highly expressed in Daoy human medulloblastoma cells and some malignant human glioma cell lines.
Due to the partial functional redundancy within a PAX subgroup we decided to investigate the expression patterns of PAX2 as well as PAX5 and PAX8. We first screened the human medulloblastoma cell line Daoy and a panel of human malignant glioma cell lines by qPCR. High PAX2 mRNA levels were found in Daoy cells as well as in the glioma cell lines T98G and A172 (Fig. 1A) . These results were confirmed by Western blot analysis and immunohistochemistry of cytopellets ( Fig. 1B and C) . While an unspecific 44-kDa signal was seen in all cell lines tested, the PAX2 specific 47-kDa signal only appeared in cell lines expressing PAX2 in accordance with qPCR results. The origin of the 44-kDa signal seems to be unspecific, as its intensity did not increase in cells transfected with PAX2 (data not shown). In contrast, PAX5 mRNA expression was restricted to Daoy cells ( Fig. 2A) . PAX8 was not detectable in Daoy cells, but five out of twelve glioblastoma cell lines showed PAX8 mRNA expression (Fig. 2B) . We also investigated the mRNA expression of PAX6, whose expression in normal human brain, gliomas and medulloblastomas and confirmed expression of PAX6 in Daoy cells, all glioma cell lines as well as the immortalized astrocytic cell line SV-FHAS (Fig. 3) .
GDNF is regulated by PAX2 in Daoy medulloblastoma cells.
Transient transfection of Daoy and T98G cells with two distinct PAX2 targeted siRNAs d1 and d2 compared to scrambled (scr) control siRNA, transfection medium or growth medium alone was performed. The specificity of the siRNAs was demonstrated by co-suppression of PAX2 as well as the PAX2 target gene GDNF in Daoy medulloblastoma cells stably overexpressing PAX2b (Fig. 4A and B) . Inversely, GDNF was upregulated in Daoy cells overexpressing PAX2b compared to neo control cells (Fig. 4C ). This fact is essential as it demonstrates both the dependency of GDNF on PAX2 expression as well as the functionality of the PAX2 vectors used in our study. GFAP, nestin, NSE and vimentin which are not known to be PAX2 targets were not regulated (data not shown). Since rapid cell death was occurring following PAX2 downregulation in Daoy cells (see below), we were not able to show the effect on PAX2 protein level in this cell line. Instead we employed the glioma cell line A172, where the effect on cell survival was less pronounced and the bladder carcinoma cell line EJ to show the effect on PAX2 protein level. Efficient gene suppression in these two cell lines was demonstrated by Western blot analysis (Fig. 4D) .
Gene suppression of PAX2 induces cytotoxic effects in Daoy and T98G cells. Transient transfection of Daoy cells with two distinct PAX2
targeted siRNAs d1 and d2 had profound cytotoxic effects as shown by crystal violet assay and phase contrast photography compared to scr control siRNA, transfection medium or growth medium alone ( Fig. 5A and B) . Flow cytometric analysis with PI-staining demonstrated an elevated rate of cell death occurring in cells treated with PAX2 specific siRNA. Cell cycle analysis employing flow cytometry showed an elevated sub-G1 peak indicating apoptosis as well as a decreased number of cells in S-and G2/M-phase (Fig. 5C) . A similar effect was observed in T98G malignant human glioma cells (Fig. 5D-F) . However, overexpression of Pax2 in glioma cell lines did not enhance proliferation, suppress apoptosis or alter growth in the syngeneic VMdK mouse model (data not shown).
PAX2 expression in glioma: in silico analyses and correlation with markers of neuronal lineage differentiation.
In glioma cell lines expression of PAX2 was observed in only a fraction. To elucidate possible mechanisms of PAX2 expression in gliomas, we followed a candidate gene approach and performed in silico analyses of glioma mRNA profiling datasets. With the candidate gene approach, we tested the hypothesis that PAX2 was part of a neuronal signature. Expression of markers known to be involved in neuronal differentiation were investigated in the panel of glioma cell lines, Daoy cells and SV-FHAS cells by qRT-PCR. The data are summarised in Fig. 3 . While several of the neuronal markers were highly expressed in glioma congruent with the increasing awareness of neuronal features in glioma (20) , no correlation of PAX2 with these markers was apparent. We also established immunohistochemistry on cell pellets of Daoy medulloblastoma and the twelve glioma cell lines as well as the stable PAX2 transfectants used in our study to assess GFAP, MAP2, NeuN, vimentin and synaptophysin protein expression. However, we observed no difference between PAX2-positive and -negative cell lines or between PAX2 overexpressing cell lines and their controls (data not shown). In silico analyses were performed with the Oncomine registry. According to the Pomeroy gene expression analysis (21) , PAX2 was upregulated 1.889-fold in classic and 1.894-fold in desmoplastic medulloblastoma samples compared to normal cerebellum probes. GDNF as a PAX2 target gene was upregulated 2.569-fold in classic and 3.97-fold in desmoplastic medulloblastoma samples ( Fig.  6A and B) . There was no correlation between PAX2 expression in medulloblastoma and the subtype-specific markers SFRP1, KCNA1, CTNNB1 or NPR3 (22) . Also no correlation between PAX2 expression and the negative predictors MYC, MYCN or CDK6 in medulloblastoma was apparent. In glioma, no significant correlation with neuronal markers defining subclasses of high-grade glioma (20) was found. Moreover, PAX2 was not inversely correlated with p53 mRNA levels (data not shown).
PAX2 expression is restricted to basket cells in the normal cerebellum and increases with the degree of dedifferentiation in medulloblastomas.
Because of the biologic function of PAX2 in hindbrain development and the published data on deregulated PAX5 expression in medulloblastomas as well as our RNA interference data in Daoy cells strongly suggesting a role for PAX2 in medulloblastomas, we investigated PAX2 protein levels in medulloblastoma samples from two separate tissue microarrays. We found that in normal cerebellum, PAX2 expression was largely absent. However, basket cells commonly had nuclear PAX2 expression (Fig. 6C) . In medulloblastomas, nuclear PAX2 expression significantly increased with a less differentiated histomorphological phenotype: while virtually all desmoplastic/nodular medulloblastomas were PAX2-negative (Fig. 6D ) and intermediate nuclear PAX2 levels were observed in the classic subtype (Fig. 6E) , the anaplastic subtype exhibited strong nuclear PAX2 expression (Fig. 6F) . The statistical analysis of PAX2 expression related to the medulloblastoma subtypes revealed significant differences (P<0.005 in Pearsons χ 2 test) showing highest PAX2 levels in medulloblastomas with the lowest histological degree of differentiation and lowest levels in medulloblastomas with higher differentiated morphology (Fig. 6G ).
Discussion
Our study demonstrates that PAX2 is aberrantly expressed and has antiapoptotic properties in medulloblastoma. Regarding the in vitro work, we found PAX2 to be overexpressed in the model medulloblastoma cell line Daoy (Fig. 1) . Importantly, by transiently transfecting Daoy medulloblastoma cells with PAX2 specific siRNA molecules we were able to induce a high level of cell death (Fig. 5) . The cytotoxic effect of downregulating PAX2 gene expression is in agreement with other studies demonstrating a potent antiapoptotic function of PAX proteins in melanoma, ovarian, bladder and prostate carcinoma cell lines (13, 23, 24) . In silico analysis of the Oncomine registry confirmed that PAX2 expression is elevated in medulloblastoma compared to normal cerebellum ( Fig. 6A and B) . However, no correlation of PAX2 expression with subtype-specific markers was found. In gliomas, neither our analysis of candidate genes (Fig. 3 ) nor in silico analyses were able to identify a neuronal signature correlating with PAX2 expression. Thus, no obvious role of expression of PAX genes in the evolution of the neuronal phenotype in gliomas was observed. Finally, our analysis of the expression of PAX2 protein in two tissue microarrays (TMA) containing 61 medulloblastoma samples not only confirmed aberrant PAX2 expression in medulloblastoma samples on the protein level but also demonstrated a correlation with a less well differentiated phenotype. Of note this analysis also identified previously unknown PAX2 expression in normal cerebellum with restriction to basket cells (Fig 6C-G) .
In conclusion, PAX2 represents a biomarker of more aggressive medulloblastoma and may have potential as a novel therapeutic target. The prognostic and predictive value of PAX2 expression should be further validated in prospective studies of medulloblastoma.
